Background: Small cell ovarian neuroendocrine (NE) carcinoma is a rare NE tumor with a low incidence, poor prognosis, and no standardized treatment. To date, there have been no clear reports on the efficacy or prognosis of combined immunological and chemotherapy-based approaches in patients with this type of tumor. Methods: We administered the immune checkpoint inhibitor tirelizumab (PD-1 mab), in combination with etoposide and cisplatin chemotherapy (EP), to a patient with small cell ovarian NE carcinoma to examine its efficacy and safety. Results: The evaluation of efficacy was PR for every 2 courses of application, and immunomaintenance therapy was administered after 6 courses of treatment. Conclusion: Our studies indicate that tirelizumab combined with EP, may be an effective treatment for small cell ovarian NE carcinoma.
第一作者机构：[1]Hebei Univ,Dept Med Oncol,Affiliated Hosp,Baoding,Hebei,Peoples R China[2]Hebei Key Lab Canc Radiotherapy & Chemotherapy, Baoding, Hebei, Peoples R China
共同第一作者：
通讯作者：
通讯机构：[1]Hebei Univ,Dept Med Oncol,Affiliated Hosp,Baoding,Hebei,Peoples R China[2]Hebei Key Lab Canc Radiotherapy & Chemotherapy, Baoding, Hebei, Peoples R China[*1]Hebei Univ,Affiliated Hosp,Hebei Key Lab Canc Radiotherapy & Chemotherapy,Dept Med Oncol,212 Yuhua E Rd,Baoding 071000,Hebei,Peoples R China
推荐引用方式(GB/T 7714)：
Zhu Yuan-Xue,Gao Xiang-Peng,Xin Lei,et al.A case report of small cell ovarian neuroendocrine carcinoma combined with immunochemotherapy[J].MEDICINE.2022,101(46):doi:10.1097/MD.0000000000031445.
APA：
Zhu, Yuan-Xue,Gao, Xiang-Peng,Xin, Lei&Jia, You-Chao.(2022).A case report of small cell ovarian neuroendocrine carcinoma combined with immunochemotherapy.MEDICINE,101,(46)
MLA：
Zhu, Yuan-Xue,et al."A case report of small cell ovarian neuroendocrine carcinoma combined with immunochemotherapy".MEDICINE 101..46(2022)
